Kitazawa et al. used the primate model, which was the first animal model to obtain FVIII equivalence for emicizumab in acquired hemophilia A. Anti-FVIII antibodies were injected in primates, which inhibited their FVIII, followed by either emicizumab (6 mg/mL) or porcine FVIII (0.01 U/mL, which cannot be detected by anti-FVIII antibody). This evidence concerns the gene F8 and hemophilia A.